Strand AI — YC W26 Launch

Strand AI is launching as part of Y Combinator's Winter 2026 batch.

The problem

Biology hasn't had its ChatGPT moment, and it's not for lack of talent or compute. The data is too sparse and fragmented.

Most patient profiles capture only 5–15 modalities out of the 80+ needed to understand human disease. Clinical trials, biomarker studies, and drug discovery programs are all bottlenecked by the same thing: missing data.

You can't run every assay on every patient. Tissue is limited, timelines are tight, and costs add up fast. So you end up with incomplete datasets, underpowered analyses, and slower paths to the clinic.

What we're building

Strand AI builds the missing data layer for biology foundation models. We take sparse, incomplete patient datasets and predict the missing modalities from the ones you already have. RNA expression from DNA/genotype, proteomics from transcriptomics + H&E, spatial transcriptomics from routine pathology slides.

We validate by downstream utility (biomarker prediction, patient stratification, clinical trial outcomes), not reconstruction loss.

Who we are

We're Oded and Yue, both former engineers at Enable Medicine. Yue built and managed ML infrastructure at scale, including a 1000+ H200 cluster. Oded shipped product to clinical and research teams.

Support us

If you're working on clinical trials, biomarker discovery, or drug development and you're missing data you wish you had, we'd love to talk.

Reach out at founders@strandai.com or find us on LinkedIn.